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Background: The IFN-α-inducible restriction factor MxB blocks HIV-1 infection after reverse transcription but prior
to integration. Genetic evidence suggested that capsid is the viral determinant for restriction by MxB. This work
explores the ability of MxB to bind to the HIV-1 core, and the role of capsid-binding in restriction.
Results: We showed that MxB binds to the HIV-1 core and that this interaction leads to inhibition of the uncoating
process of HIV-1. These results identify MxB as an endogenously expressed protein with the ability to inhibit HIV-1
uncoating. In addition, we found that a benzimidazole-based compound known to have a binding pocket on the
surface of the HIV-1 capsid prevents the binding of MxB to capsid. The use of this small-molecule identified the
MxB binding region on the surface of the HIV-1 core. Domain mapping experiments revealed the following
requirements for restriction: 1) MxB binding to the HIV-1 capsid, which requires the 20 N-terminal amino acids,
and 2) oligomerization of MxB, which is mediated by the C-terminal domain provides the avidity for the interaction
of MxB with the HIV-1 core.
Conclusions: Overall our work establishes that MxB binds to the HIV-1 core and inhibits the uncoating process of
HIV-1. Moreover, we demonstrated that HIV-1 restriction by MxB requires capsid binding and oligomerization.
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The myxovirus resistance proteins (Mxs) represent a
family of interferon-inducible factors with a wide range
of antiviral activities [1,2]. The MxB gene was originally
cloned from a human glioblastoma cell line treated with
interferon-α (IFN-α) [3,4]. MxB as well as the related
protein MxA belongs to the dynamin-like family of pro-
teins, which have diverse functions ranging from vesicle
transport to antiviral activity [1,5-10]. The most studied
dynamin-like protein that exhibits antiviral activity is
MxA [1,2]. Contrary to MxB, the antiviral role of MxA
has been extensively studied for viruses including influ-
enza [1,11-14], tick-born Thogoto [15], African swine
fever [16], hepatitis B [17], and La Crosse [18,19]. Only* Correspondence: Felipe.Diaz-Griffero@einstein.yu.edu
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unless otherwise stated.recently the antiviral activity of the long form of MxB
was described [8,20-22]; these investigations lead to the
discovery that the IFN-α-inducible protein MxB blocks
HIV-1 infection.
Genetic evidence suggested that HIV-1 capsid is the
determinant for the ability of MxB to block HIV-1 infec-
tion [8,21,22]. HIV-1 viruses bearing capsid changes
such as P90A, G89V and N57S escape MxB restriction
suggesting that capsid is the determinant for the block
imposed by MxB. These experiments imply that MxB is
directly interacting with the HIV-1 core early during in-
fection. However, the ability of MxB to associate with
HIV-1 cores has not been explored.
MxB blocks HIV-1 infection after the occurrence of
reverse transcription but before integration [8,21,22].
This evidence suggested that MxB might be interfering
with one or more of the following processes: 1) HIV-1
uncoating, 2) nuclear import of the HIV-1 pre-integration
complex, or 3) nuclear maturation of the pre-integration
complex. However, the mechanism by which MxB inter-
feres with early steps of HIV-1 infection is not understood.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HIV-1 core in vitro and during infection. We showed that
MxB interacts with in vitro assembled HIV-1 capsid-
nucleocapsid (CA-NC) complexes, which recapitulate the
surface of the HIV-1 core. In agreement, we found that
MxB associates with HIV-1 cores during infection using
the fate of the capsid assay. Remarkably, the binding of
MxB to the HIV-1 core inhibits the uncoating process of
HIV-1 defining MxB as an endogenously expressed
protein that prevents HIV-1 uncoating. To find small-
molecule inhibitors that prevent the binding of MxB to
the HIV-1 core, we screened a battery of structurally well-
known HIV-1 capsid inhibitors for their ability to prevent
the binding of MxB to the HIV-1 core. Interestingly, a
benzimidazole-based compound known to have a binding
pocket on the surface of the HIV-1 capsid prevents the
binding of MxB to the capsid. These experiments suggested
an overlap between the capsid binding sites for MxB and
the benzimidazole-based compound. Assaying the contri-
bution of the different MxB protein domains to capsid
binding and restriction revealed that the 20 N-terminal
amino acids are responsible for the ability of MxB to bind
to the HIV-1 core. In addition, we provide evidence that
the C-terminal leucine zipper domain of MxB provides
the necessary avidity for the interaction of MxB with the
HIV-1 core. Overall, our studies showed that MxB binds
to the HIV-1 core and inhibits the uncoating process of
HIV-1 leading to an infection block.
Results
MxB binds in vitro assembled HIV-1 CA-NC complexes
To test the ability of MxB to restrict HIV-1 infection, we
stably expressed FLAG-tagged MxB in human HeLa, hu-
man U937 and dog Cf2Th cells using the LPCX vector
system and tested for the ability of these cells to restrict
HIV-1 and other retroviruses (Additional file 1A, B and C),
as described [23]. In agreement with recent publications
[8,20-22], the long form of MxB potently blocks HIV-1 in-
fection in all tested cell lines. Because the use of HIV-1 vi-
ruses bearing capsid changes suggested that the HIV-1
capsid is the determinant for MxB restriction, we exam-
ined the ability of MxB to associate with the HIV-1 core.
For this purpose, we tested the ability of MxB to bind
in vitro assembled HIV-1 capsid-nucleocapsid (CA-NC)
complexes, as described [24-26]. In vitro assembled HIV-1
CA-NC complexes recapitulate the surface of the HIV-1
core, and are an established model to evaluate the abil-
ity of cellular factors to interact with the HIV-1 core
[25,27-29]. As shown in Figure 1A, MxB binds to in vitro
assembled HIV-1 CA-NC complexes in a similar manner
when compared to the HIV-1 capsid interacting molecule
rhesus TRIM5α (TRIM5αrh) [25,29]. Stable expression
of MxB or TRIM5αrh potently blocked HIV-1 infec-
tion (Additional file 2A).To further test the role of MxB binding to HIV-1 cap-
sid in restriction, we tested the ability of MxB to bind
in vitro assembled HIV-1 CA-NC complexes bearing the
capsid changes P90A, G89V or N57S, which when incor-
porated into the virus allow HIV-1 to partially escape
MxB restriction [8,21,22]. As shown in Figure 1B, MxB
binds to in vitro assembled HIV-1 CA-NC complexes
bearing the capsid change P90A, suggesting that binding
is necessary but not sufficient for restriction. Interest-
ingly, MxB bound less to in vitro assembled HIV-1 CA-
NC complexes bearing changes G89V and N57S when
compared to wild type complexes (Figure 1B). As previously
shown, HIV-1 bearing the capsid change P90A, G89V or
N57S partially escaped MxB restriction (Additional file 2B).
Notwithstanding HIV-1 viruses bearing the capsid change
P90A, G89V or N57S partially escape MxB restriction, we
found that P90A is the only capsid change that did not re-
sult in a virus with an infectivity defect (Additional file 2C).
To confirm the bona fide origin and functionality of
in vitro assembled HIV-1 CA-NC complexes tubes bear-
ing capsid mutants P90A, G89V and N57S, we tested the
binding of cleavage and polyadenylation specific factor 6
(CPSF6) to the different capsid mutants. CPSF6 was able
to bind in vitro assembled HIV-1 CA-NC complexes bear-
ing changes P90A and G89V, but not N57S (Additional
file 2D). In addition, we showed the ability of TRIM5αrh
to bind in vitro assembled HIV-1 CA-NC complexes bear-
ing the change N57S (Additional file 2D).
Furthermore, we performed electron microscopy to
show that the in vitro assembled HIV-1 CA-NC mutants
form similar tubular structures when compared to wild
type (Additional file 2E).
Next we tested whether MxA, which is the closest hu-
man homolog to MxB that contains antiviral activity [2],
binds to in vitro assembled HIV-1 CA-NC complexes.
MxB is composed of the same domains when compared
to MxA with the exception that MxB exhibits a longer
N-terminal domain (Figure 1C, bottom panel) [5]. Inter-
estingly, MxA was not able to interact with in vitro as-
sembled HIV-1 CA-NC complexes when compared to
MxB (Figure 1C, upper left panel). In agreement, MxA
was not able to block HIV-1 infection when compared to
MxB (Figure 1C, upper right panel) [8]. Next we tested
the capsid binding ability of a protein chimera containing
residues 1–90 of MxB fused to residues 43–662 of MxA
[MxB (1–90)-MxA (43–662)]. Contrary to MxA, the pro-
tein chimera MxB (1–90)-MxA (43–662) gained the abil-
ity to bind in vitro assembled HIV-1 CA-NC complexes
(Figure 1C, left panel). These results suggested that the
N-terminal region of MxB is involved in its ability to bind
capsid. In addition, MxB (1–90)-MxA (43–662) gained the
ability to block HIV-1 infection (Figure 1C, right panel).
Furthermore, these results correlated the ability of MxB to
bind capsid with HIV-1 restriction.
Figure 1 MxB binds in vitro assembled HIV-1 CA-NC complexes. (A) The ability of MxB to bind in vitro assembled HIV-1 CA-NC complexes
was measured as described in Methods. Input and Bound fractions were analyzed by Western blotting using anti-HA or anti-p24 antibodies.
Similar results were obtained in three independent experiments, and the standard deviation for the bound fraction relative to input is shown.
(B) The ability of MxB to bind in vitro assembled HIV-1 CA-NC complexes’ bearing the capsid changes P90A, G89V and N57S was measured as
described above. Similar results were obtained in three independent experiments. (C) The ability of MxA, MxB and the protein chimera MxB
(1–90)-MxA (43–662) to bind in vitro assembled HIV-1 CA-NC were measured as described above (left panel). Cf2Th cells stably expressing MxA,
MxB, or MxB (1–90)-MxA (43–662) were challenged with increasing amounts of HIV-1-GFP viruses. Infection was determined by measuring the
percentage of GFP-positive cells (right panel). MxA, MxB and MxB (1–90)-MxA (43–662) proteins are depicted (lower panel). Similar results were
obtained in three independent experiments. NLS: nuclear localization signal. B: comprises the bundle signaling element. G: contains a GTPase
domain. Stalk: domain that mediates assembly into oligomers. (D) Increased HIV-1 capsid colocalization with MxB upon infection. CF2Th cells
stably expressing MxB, MxB-Δ(1–20), or containing the empty vector LPCX, were spinoculated with VSV-G pseudotyped R7ΔEnv virions for 2 h.
Cells were fixed 3 and 6 hours post-infection. Colocalization of MxB with HIV capsid (p24) is shown 6 hours post infection. The percentage of p24
associated with MxB was quantified by counting the number of p24 positive virions, which are positive for MxB is shown. Between 20–25 images
were analyzed per condition using the Imaris Software as described in Methods. Bafilomycin A1 (Baf1). Data is representative of 3 independent
experiments. **, P <0.05.
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ize with MxB in living cells using fluorescence microscopy
over time, as described [30]. For this purpose, we infected
Cf2Th cells stably expressing MxB with VSV-G pseudo-
typed R7ΔEnv HIV-1 viruses in the presence or absence of
Bafilomycin A1, which inhibits the entry of pH-dependent
viruses [31]. At 6 hours post-infection, samples were fixed
and MxB colocalization with HIV-1 cores was quantified(Figure 1D). The percentage of p24 that colocalizes with
MxB was calculated as the number of p24 positive virions
that are associated with MxB as described in Methods
(Figure 1D, lower panel). As a control, we performed simi-
lar experiments in cells expressing MxB-Δ(1–20), which
is a deletion mutant that no longer binds capsid or re-
strict HIV-1 (see below). Colocalization between MxB-Δ
(1–20) and p24 was not observed. These results showed
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gesting that MxB directly associates with HIV-1 cores in
living cells.
In agreement with the fact that MxB modestly blocks
SIVmac and HIV-2 infection (Additional file 1C), we
found that MxB binds to in vitro assembled SIVmac and
HIV-2 CA-NC complexes (Additional file 1D).
Overall, these results showed that MxB binds to HIV-1
capsid, and that binding to capsid is necessary for the ability
of MxB to block HIV-1 infection. By the use of the protein
chimera MxB (1–90)-MxA (43–662), we have correlated
binding with restriction. Additionally, we showed that the
N-terminal 90 amino acids of MxB are important for the
ability of MxB to bind the HIV-1 capsid and restriction of
HIV-1 infection.
MxB binds to the HIV-1 core and inhibits the uncoating
process during infection
To investigate whether MxB interacts with the HIV-1
core during infection, we performed the fate of the capsid
assay to follow the protein composition of HIV-1 cores
during infection. The fate of the capsid assay examines the
uncoating process of HIV-1 and measures the amount of
soluble versus pelletable capsids (HIV-1 cores) during in-
fection in living cells, as described [25,28,32]. Input, soluble
and pellet fractions were analyzed by Western blotting
using antibodies against p24. Pellet fractions were also an-
alyzed for the presence of MxB by Western blotting using
anti-FLAG antibodies. As shown in Figure 2A (left panel),
MxB is present on HIV-1 cores isolated from HIV-1 in-
fected Cf2Th cells stably expressing MxB. As a control,
we observed the absence of MxB in pelletable fractions
prepared from uninfected control cells (Figure 2A, right
panel). These results suggested that MxB interacts with
the HIV-1 core during infection. Remarkably, we noticed
an increase in the amount of pelletable capsid when com-
paring cells stably expressing MxB with cells containing
the empty vector LPCX (Figure 2A, left panel). These ex-
periments suggested that MxB inhibits the uncoating
process of HIV-1. In parallel, we performed the fate of the
capsid in cells stably expressing TRIM5αrh, which acceler-
ates uncoating (Figure 2A) [25,32].
Consequently, we tested the ability of MxB to inhibit the
uncoating process of HIV-1 mutants that partially over-
come restriction. For this purpose, we challenged Cf2Th
cells stably expressing MxB or containing the empty vector
LPCX with similar amounts of HIV-1-P90A, HIV-1-G89V
or HIV-1-N57S viruses (Figure 2B), which partially es-
cape MxB restriction [8,21,22]. MxB only minimally
inhibits the uncoating process of HIV-1 viruses bear-
ing capsid changes P90A, G89V and N57S (Figure 2B).
Accordingly, MxB partially affected the infection of
HIV-1-P90A, HIV-1-G89V and HIV-1-N57S viruses.
In agreement with our binding assays, we also observedthat HIV-1 cores bearing the different capsid mutations
were able to recruit MxB.
We and others have previously observed that cells ex-
pressing the CPSF6 protein fused to a nuclear export
signal (NES-CPSF6) inhibits the uncoating process of
HIV-1 [33,34]; therefore, we compared the abilities of
MxB and NES-CPSF6 to inhibit the uncoating process of
HIV-1. As shown in Figure 2C, MxB is as potent as NES-
CPSF6 in inhibiting the uncoating process of HIV-1. As
expected, MxB, NES-CPSF6 and TRIM5αrh potently re-
stricted HIV-1 infection (Additional file 2F).
Next we tested the ability of IFN-α-treated human
HT1080 cells to inhibit the uncoating process of HIV-1.
For this purpose, we challenged human HT1080 cells that
were treated or not with IFN-α with similar amounts of
HIV-1-GFP and performed the fate of the capsid assay. As
shown in Figure 2D, IFN-α-treated HT1080 cells inhibit
the uncoating process of HIV-1. These findings suggested
that IFN-α-treated HT1080 cells prevent the uncoating
process of HIV-1, which could be mediated by any of
the IFN-α inducible genes. In agreement with our previ-
ous findings, endogenously expressed MxB co-sedimented
with pelletable capsids suggesting that endogenously
expressed MxB interacts with the HIV-1 core in living
cells. As expected, IFN-α-treated human HT1080 expressed
endogenous MxB and potently blocked HIV-1 infection
(Figure 2D, right panels).
Subsequently, we tested whether MxB is able to retain
HIV-1 cores in the cytoplasm of infected living cells by
fluorescence microscopy. For this purpose, we challenged
Cf2Th cells stably expressing MxB, MxB-Δ(1–20), or con-
taining the empty vector LPCX, with dually labeled HIV-1
particles containing Vpr-GFP and the S15-mCherry, as de-
scribed [30]. Infected cells were fixed at the indicated time
points, and the number of fused virions (S15-mCherry
negative particles) was counted in 10 different visual fields.
As shown on Figure 2E, infected Cf2Th cells express-
ing MxB allowed the accumulation of viral cores over
time when compared to infected Cf2Th stably cells
expressing MxB-Δ(1–20) or containing the empty vec-
tor LPCX. These results suggested that expression of
MxB allows the accumulation of HIV-1 cores in the
cytoplasm over time.
The interaction between MxB and the HIV-1 core is
prevented by a benzimidazole-based inhibitor that
binds to a specific pocket in the HIV-1 capsid
To better understand the binding of MxB to the HIV-1
core, we tested the ability of a battery of small molecules
that target capsid to prevent the binding of MxB to
in vitro assembled HIV-1 CA-NC complexes [35]. For this
purpose, we examined the binding of MxB to in vitro
assembled HIV-1 CA-NC complexes in the presence
of small-molecules that target HIV-1 capsid. In these
Figure 2 (See legend on next page.)
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Figure 2 MxB binds to the HIV-1 core and inhibits the uncoating process of HIV-1 during infection. (A) Cf2Th cells stably expressing
FLAG-tagged MxB (MxB-FLAG), TRIM5αrh or containing the empty vector LPCX were challenged using similar amounts of HIV-1. Sixteen hours
post-infection samples were processed for the fate of the capsid assay as described in Methods. Input, soluble and pellet fractions were analyzed
by Western blotting using anti-p24 antibodies (left panel). The binding of MxB to the viral core was assayed by Western blotting using anti-FLAG
antibodies (left panel). The quantification of pelletable fractions relative to the pellet found when infecting cells containing the LPCX control
vector by wild type HIV-1 was calculated for each experiment. Similar results were obtained in three independent experiments, and the standard
deviations are shown. To control for the presence of MxB-FLAG in pelletable fractions when using mock-infected cells, Cf2Th cells stably expressing
MxB-FLAG were challenged with HIV-1 or not, and processed for the fate of the capsid assay (right panel). Input and pellet fractions were analyzed by
Western blotting using anti-p24 and anti-FLAG antibodies. Similar results were obtained in three independent experiments and a representative
experiment is shown. (B) Cf2Th cells stably expressing MxB or stably transduced with the empty vector LPCX were challenged using similar
amounts of HIV-1-P90A (left panel), HIV-1-G89V (middle panel) or HIV-1-N57S (right panel). Sixteen hours post-infection samples were processed for the
fate of the capsid assay. Input, soluble and pellet fractions were analyzed by Western blotting using anti-p24 antibodies. The quantification of pelletable
fractions relative to the pellet found when infecting cells containing the LPCX control vector by wild type HIV-1 was calculated for each experiment.
Similar results were obtained in three independent experiments, and the standard deviations are shown. (C) Cf2Th cells stably expressing MxB,
NES-CPSF6, TRIM5αrh or containing the empty vector LPCX were challenged using similar amounts of HIV-1. Sixteen hours post-infection samples were
processed for the fate of the capsid assay. Input, soluble and pellet fractions were analyzed by Western blotting using anti-p24 antibodies. Similar
results were obtained in three independent experiments, and the standard deviation for pelletable fractions relative to the pellet found in cells
containing the empty vector LPCX are shown. (D) IFN-α-treated (1000U/ml for 24 hours) or untreated Human HT1080 cells were challenged using
similar amounts of HIV-1. Sixteen hours post-infection samples were processed for the fate of the capsid assay (left panel). Quantification of pelletable
fractions relative to the pellet found when infecting untreated HT1080 cells by wild type HIV-1 was calculated for each experiment. Similar results were
obtained in three independent experiments, and the standard deviations are shown. Induction of MxB expression in human HT1080 cells by the
indicated amounts of IFN-α after 24 hours of exposure is shown (upper right panel). The ability of IFN-α-treated HT1080 cells to block HIV-1 infection is
shown (bottom right panel). (E) MxB causes retention of HIV virions in the cytoplasm. Cf2Th cells stably expressing MxB, MxB-Δ(1–20), or containing
the empty vector LPCX, were spinoculated with fluorescently labeled HIV-1 virions for 2 h. HIV-1 viruses were fluorescently labeled with Vpr-GFP
(label the inside of the virus) and the S15-mCherry (labels the lipid membrane of the virus). Cells were fixed and analyzed 3 and 6 hours post-infection.
The total number of fused viruses (S15-mCherry negative particles) is shown, as determined by counting 10 fields using the Imaris software. On the left
panel, the relative number of fused virions normalized to input viruses overtime are shown. On the right panel, the percentage of total fused virions
retained in the cytoplasm overtime is shown. Results are representative of 3 independent experiments. ***, P <0.001 and **, P <0.05, as compared with
respective controls.
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[35,39,40], 4-{2-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-
1-[3-(1H-imidazol-1-yl) propyl]-1H-benzimidazol-5-yl}
benzoic acid dihydrochloride (CPIPB) [41,42], and the
peptide CAI [35,43]. Interestingly, only CPIPB inhibited
the ability of MxB to bind in vitro assembled HIV-1 CA-
NC complexes (Figure 3A, upper left panel). As a control,
we tested the ability of these compounds to block the
binding of CPSF6, TRIM5αrh and TRIMCyp to in vitro as-
sembled HIV-1 CA-NC complexes (Figure 3A). As ex-
pected, the drugs PF74 and BI-2 affected the ability of
CPSF6 to bind capsid due to the fact that PF74, BI-2 and
CPSF6 bind to similar regions on the HIV-1 capsid
(Figure 3A) [33,44]. Similarly, the binding of TRIMCyp
to capsid was only affected by cyclosporine A (CsA),
which is an inhibitor of cyclophilin A (Cyp A) (Figure 3A).
To further understand the ability of CPIPB to prevent the
binding of MxB to in vitro assembled HIV-1 CA-NC com-
plexes, we performed a dose–response curve for the
different drugs (Figure 3B). We observed that using
CPIPB at 200 μM completely inhibited the binding of
MxB to capsid. As a control, we showed that the use of
BI-2, CAP-1 or PF74 at 200 μM or higher concentrations
did not affect the binding of MxB to capsid. These experi-
ments suggested that the capsid-binding site for MxB
overlaps with the binding pocket for CPIPB, which islocated between the base of the Cyp A binding loop and
the loop that connects helices 6 and 7 of HIV-1 capsid
(Figure 3C). The fact that the HIV-1 capsid binding site
for MxB is next to the base of the Cyp A binding loop is
in agreement with previous observations suggesting that
CsA partially relieves MxB restriction to HIV-1 and that
HIV-1-P90A and HIV-1-G89V viruses partially escape
restriction [8,22]. Although CsA partially relieves MxB
restriction (Figure), it did not affect the ability of MxB
to bind in vitro assembled HIV-1 CA-NC complexes
(Additional file 3B). As a control, we observed that
CsA relieved TRIMCyp restriction and binding to capsid
(Additional file 3A and B). In addition, we tested whether
MxB recruits Cyp A to the HIV-1 capsid. As shown in
Additional file 3C, MxB did not increase the amount of
endogenous Cyp A recruited to the capsid. As a control,
we showed that the use CsA prevented the binding of
endogenous Cyp A to the HIV-1 capsid (Additional
file 3C). Altogether these results suggested that the bind-
ing of MxB to HIV-1 capsid is specific and can be modu-
lated by a small-molecule inhibitor.
Next we tested the ability of CPIPB to release HIV-1
restriction in mammalian cells expressing MxB. How-
ever, we could not measure release of restriction since
we found that CPIPB is highly toxic for mammalian cells
above 50 μM.
Figure 3 The interaction of MxB with the HIV-core is inhibited by a small-molecule that binds into a pocket between the bases of the
Cyp A binding loop and the loop that connects helices 6 and 7 of HIV-1 capsid. (A) The ability of MxB-FLAG (upper left panel), CPSF6-FLAG
(upper right panel), TRIM5αrh-HA (lower left panel), and TRIMCyp-HA (lower right panel) to bind in vitro assembled HIV-1 CA-NC complexes was
measured in the presence of the indicated concentration of the small molecules PF74, BI-2, CPIPB (4-{2-[3-(3-clorophenyl)-1H-pyrazol-4-yl]-1-[3-
(1H-imidazol-1-yl-propyl]-1H-benzimidazol-5-yl} benzoic acid), CAP-1 and the peptide CAI, as described in Methods. Similar results were obtained
in three independent experiments and a representative experiment is shown. (B) The ability of MxB to bind in vitro assembled HIV-1 CA-NC
complexes in the presence of the indicated concentrations of the small molecule CPIPB (upper left panel), BI-2 (upper right panel), CAP-1 (bottom
left panel) and PF74 (bottom right panel) was measured. Similar results were obtained in three independent experiments and a representative
experiment is shown. (C) Chemical structure of the small molecule CPIPB is shown (left panel). Surface representation of the X-ray structure of
the HIV-1 capsid in complex with CPIPB (PDB entry 4E91) (middle panel). Surface representation of the X-ray structure of the HIV-1 CA hexamer
(PDB entry 3H4E) showing in orange residues that directly interact with CPIPB on the surface of the HIV-1 capsid.
Fricke et al. Retrovirology 2014, 11:68 Page 7 of 14
http://www.retrovirology.com/content/11/1/68Contribution of the different protein domains of MxB to
HIV-1 capsid-binding and restriction
MxB contains several different protein regions: a nuclear
localization signal (NLS), G domain, stalk region, and
a leucine zipper motif (Figure 4A). To understand thecontribution of the different MxB domains to capsid-
binding and restriction, we generated a series of deletion
constructs (Figure 4A and Table 1). Our observations re-
vealed that deletion of the 20 N-terminal amino acids
of MxB abolished the ability of the protein to bind
Figure 4 Contribution of the different domains of MxB to capsid binding and restriction of HIV-1. (A) Wild type human MxB protein is
depicted in the top figure. The numbers of the amino acid residues at the boundaries of the MxB domains are indicated. The different MxB
variants are shown. (B) The ability of wild type and mutant MxB proteins to bind in vitro assembled HIV-1 CA-NC complexes was measured, as
described in Methods. Similar results were obtained in three independent experiments, and the standard deviation for bound fractions relative to
input are shown. (C) Cf2Th cells stably expressing wild type and the indicated MxB variant were analyzed by Western blotting using anti-FLAG
antibodies. As loading control, cell lysates were Western blotted using anti-GAPDH antibodies. (D) Cf2Th cells stably expressing wild type and
the indicated MxB variants were challenged with increasing amounts of HIV-1 viruses expressing GFP as a reporter for infection (HIV-1-GFP).
Forty-eight hours post-infection the percentage of GFP-positive cells was determined by flow cytometry. As a control, Cf2Th cells stably
transduced with the empty vector LPCX were challenged with increasing amounts of HIV-1-GFP. Similar results were obtained in three
independent experiments and a representative experiment is shown.
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Additional file 4 and Table 1). These results are in agree-
ment with the ability of MxB (1–90)-MxA (43–662)
to bind capsid, which suggests that the N-terminal resi-
dues of MxB are involved in its ability to bind HIV-1 cap-
sid. As shown in Figure 4B, deletion of the C-terminal
domain of MxB, which contains a leucine zipper, de-
creased the ability of MxB to bind in vitro assembled
HIV-1 CA-NC complexes. Next we tested the abilityof the different MxB variants to block HIV-1 infection.
For this purpose, we stably expressed the different
MxB variants in Cf2Th cells (Figure 4C), and chal-
lenged them using increasing amounts of HIV-1-GFP
(Figure 4D). Interestingly, N-terminal or C-terminal
deletions affected the ability of MxB to block HIV-1
infection. These results suggested that the N-terminal
and C-terminal domain of MxB are important to
block HIV-1 infection.
Table 1 Phenotypes of MxB variants
MxB variant Restriction
of HIV-1a
Binding to HIV-1 Oligomerizationc
CA-NC Complexesb
WT + +++ +
Δ (1–20) - - +
Δ (1–43) - - ND
Δ (1–60) - - +
Δ (1–84) - - ND
Δ (1–102) - ND ND
Δ (1–387) ND - ND
Δ (572–715) - + -
Δ (623–715) - + -




L661k - + -
WT, Wild type.
ND, Not determined.
aRestriction was measured by infecting cells expressing the indicated MxB
variant with HIV-1-GFP. After 48 hours, the percentage of GFP-positive cells
(infected cells) was determined by flow cytometry. “+”: indicates restriction,
“-”: indicates absence of restriction. ND: Not Determined.
bBinding to the HIV-1 capsid complexes was determined for each MxB variant
as described in Methods. “+++”: indicates 100% binding which corresponds to the
amount of wild type MxB bound to HIV-1 CA-NC complexes, “+”: indicates ~10%
binding compared to wild type MxB when expressed at similar levels, “-”:
indicates no binding. Experiments were repeated at least three times, and
standard deviations are shown in Figure legends.
cWild type and mutant MxB-FLAG proteins were assayed for association with
wild-type MxB-HA as described in Methods. “+”: oligomerization observed in
wild-type MxB when expressed at similar levels. ND: Not Determined.
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bind to the HIV-1 core
To examine the contribution of oligomerization to the
ability of MxB to bind capsid and restrict HIV-1, we
tested the oligomerization ability of the different MxB
variants. We evaluated the biochemical ability of MxB
containing a FLAG tag (MxB-FLAG) to interact with
MxB containing an HA tag (MxB-HA). For this purpose,
we cotransfected cells using similar amounts of both
MxB-FLAG and MxB-HA constructs. Cells were lysed,
and MxB-FLAG was immunoprecipitated by using anti-
FLAG beads, as described in Methods. Proteins eluted
by the FLAG peptide were analyzed by Western blotting
using anti-HA and anti-FLAG antibodies (Figure 5A). In
agreement with the notion that MxB forms oligomers,
MxB-FLAG interacts with MxB-HA (Figure 5A). These
results showed that MxB forms oligomers when expressed
in mammalian cells, as it has been shown using the same
methodology for MxA [11]. Next we measured the ability
of the different MxB-FLAG variants to oligomerize with
MxB-HA (Figure 5B). After testing all the variants that
exhibited comparable expression to wild type MxB, we
found that only MxB variants Δ(572–715) and Δ(623–715)
lost their ability to oligomerize (Figure 5B and Table 1),suggesting that the C-terminal residues of MxB are in-
volved in oligomerization. These results are in agreement
with the presence of a leucine zipper motif in the C-
terminal region of MxB (Figure 4A); this leucine zipper has
been postulated to be important for the oligomerization
ability of MxA [45,46]. Therefore, we disrupted the leucine
zipper of MxB by a changing a single amino (L661K). Dis-
ruption of the leucine zipper by a single point mutation
disrupted the ability of MxB to oligomerize (Figure 5C). In
agreement with our deletion experiments, MxB-L661K
neither bound in vitro assembled HIV-1 CA-NC com-
plexes nor restricted HIV-1 infection (Figure 5D and E).
These results suggested that oligomerization provides the
necessary avidity for MxB to bind HIV-1 capsid and is re-
quired for restriction (Table 1).
Discussion
The present work explores the ability of MxB to bind to
the HIV-1 core, and the contribution of binding to HIV-1
restriction. Our findings provided novel insights into the
mechanism used by MxB to block HIV-1 infection: 1) MxB
binds to the HIV-1 capsid, 2) MxB colocalizes with HIV-1
cores in infected cells as determined by fluorescence mi-
croscopy, 3) MxB is associated biochemically with pelleta-
ble cores during infection, 4) MxB inhibits the uncoating
process of HIV-1 during infection as measured by the fate
of the capsid assay and a microscopy-based assay, 5) the
small-molecule inhibitor CPIPB, which binds into a pocket
between the bases of the Cyp A binding loop and the loop
that connects helices 6 and 7 of HIV-1 capsid (Figure 3C)
[41,42], interfered with the ability of MxB to bind HIV-1
capsid, 6) domain mapping experiments and the use of a
protein chimera showed that capsid binding correlates with
restriction, and 6) disruption of MxB’s leucine zipper motif
abrogated the ability of MxB to oligomerize, to bind capsid
and to block HIV-1 infection.
We tested the ability of MxB to bind in vitro assembled
HIV-1 CA-NC complexes, and showed that MxB binds to
the HIV-1 capsid in a similar manner when compared to
the restriction factor TRIM5αrh [25,29]. The testing of
MxB binding to capsid mutants P90A, G89V and N57S
revealed that binding is necessary but not sufficient for re-
striction. By using the fate of the capsid assay, we also
showed that MxB is contained in pelletable fractions sug-
gesting that MxB associates with the HIV-1 core during
infection. In agreement, fluorescence microscopy experi-
ments showed that colocalization of HIV-1 cores with
MxB increased over time in infected cells suggesting that
MxB associates with the HIV-1 core.
We also compared the capsid-binding abilities of MxB
with MxA, which does not restrict HIV-1 infection [6,8].
Our experiments showed that MxA does not bind in vitro
assembled HIV-1 CA-NC complexes. MxA and MxB ex-
hibit similar sequences and domains suggesting analogous
Figure 5 Contribution of oligomerization to the binding of MxB to the HIV-1 core. (A) MxB oligomerization assay. Human 293T cells were
cotransfected with plasmids expressing wild type MxB-HA and MxB-FLAG proteins. Cells were lysed 24 hours post-transfection and analyzed by
Western blotting using anti-HA and anti-FLAG antibodies (Input). Subsequently, lysates were immunoprecipitated by using anti-FLAG agarose
beads, as described in Methods. Anti-FLAG agarose beads were eluted using the 3X FLAG peptide. Elutions were analyzed by Western blotting
using anti-HA and anti-FLAG antibodies (Immunoprecipitation). WB, Western blot; IP, Immunoprecipitation; WT, wild type. (B) Oligomerization of
MxB variants. Human 293T cells were cotransfected with a plasmid expressing wild type MxB-HA and a plasmid either expressing wild type or the
indicated mutant MxB-FLAG protein. Similarly, FLAG-tagged proteins were immunoprecipitated, and elutions were analyzed by Western blotting
using anti-HA and anti-FLAG antibodies. (C) Oligomerization of the MxB’s leucine zipper domain mutant L661K. Human 293T cells were cotransfected
with a plasmid expressing wild type MxB-HA and a plasmid either expressing wild type or the mutant MxB-L661K-FLAG protein. Similarly, FLAG-tagged
proteins were immunoprecipitated, and elutions were analyzed by Western blotting using anti-HA and anti-FLAG antibodies. (D) The ability of
MxB-L661K-FLAG to bind in vitro assembled HIV-1 CA-NC complexes was measured, as described Methods. (E) Cf2Th cells stably expressing wild
type or the indicated mutant MxB protein (upper panel) were challenged with increasing amounts of HIV-1-GFP. Forty-eight hours post-infection the
percentage of GFP-positive cells was measured by flow cytometry (lower panel). As a control, Cf2Th cells stably transduced with the empty vector
LPCX were challenged with HIV-1. Similar results were obtained in three independent experiments and a representative experiment is shown.
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MxA and MxB is that the latter contains an additional
60 amino acids on the N-terminal end, which might
be directly involved in the binding of MxB to capsid.In agreement with this hypothesis, we showed that the
protein chimera MxB (1–90)-MxA (43–662) gains the
ability to bind HIV-1 capsid and to restrict HIV-1
when compared to MxA. These results suggested that
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ability of MxB to bind capsid and restrict HIV-1.
This work shows that MxB inhibits the HIV-1 uncoat-
ing process during infection. Using the fate of the capsid
assay, which analyses the HIV-1 uncoating process dur-
ing infection [25,28,47], we showed that MxB stabilizes
the HIV-1 core during infection. In agreement with
these observations, we also showed that MxB facilitates
the accumulation of HIV-1 cores over time by fluores-
cence microscopy in living cells. Overall our results
showed that the IFN-α inducible MxB protein is a natur-
ally expressed protein that inhibits the uncoating process
of HIV-1.
To explore MxB’s binding site on the surface of the
HIV-1 capsid, we tested a battery of capsid inhibitors
that are well studied with respect to their binding sites
on the HIV-1 capsid protein. From these investigations,
we found that the compound CPIPB was able to com-
pete with MxB for binding to capsid suggesting that the
binding pocket of CPIPB overlaps with the binding site
for MxB [41,42]. The binding pocket for CPIPB is lo-
cated between the base of the Cyp A binding loop and
the loop that connects helices 6 and 7 of HIV-1 capsid
(Figure 3C). Remarkably, CPIPB binding to capsid facili-
tates crystallization of capsid by decreasing the mobility
of the Cyp A binding loop and the loop that connects
helices 6 and 7 of HIV-1 capsid [41,42]. In agreement,
the binding of MxB to the HIV-1 capsid stabilizes the
HIV-1 core suggesting that this particular capsid region
modulates stability of the HIV-1 core.
Domain mapping studies showed that the 20 N-
terminal amino acids are essential for the ability of MxB
to bind HIV-1 capsid and restrict infection. AlthoughFigure 6 MxB binds to the HIV-1 core and prevents the uncoating proMxB-Δ(1–20) did not bind capsid or restrict HIV-1, it
retained its oligomerization ability. These experiments
suggested that the N-terminal domain is important for the
ability of MxB to restrict HIV-1 infection. Future experi-
ments destined to understand the structure of this region
will shed light on the domain used by MxB to interact
with the HIV-1 core.
Finally, we established that MxB’s oligomerization by
its leucine zipper domain is important for its ability to
bind capsid and restrict infection. Deletion and point
mutations of MxB’s leucine zipper motif suggested that
oligomerization contributes to MxB’s binding avidity for
the HIV-1 core.
Overall our investigations suggested a model in which
MxB encounters the HIV-1 core in the cytoplasm of the
cell and prevents the uncoating process of HIV-1 (Figure 6).
Our current understanding of uncoating suggests that
HIV-1 reverse transcription occurs before or during the
uncoating process of HIV-1 [25,47-50]. Interestingly, in-
hibition of uncoating by the use of proteasome inhibitors
augments the occurrence of reverse transcription suggest-
ing that reverse transcription can occur inside the HIV-1
core [23,32]. Similarly, inhibition of HIV-1 uncoating by
NES-CPSF6 allows the occurrence of reverse transcription
[33,34,51]. Therefore, it is feasible to propose that when
MxB inhibits the uncoating process of HIV-1; it allows the
occurrence of reverse transcription inside the HIV-1 core
and traps the viral DNA. Trapping the viral DNA inside
the core may prevent the transport of the viral DNA into
the nucleus, in agreement with a block before nuclear
import [21,22]. Similarly, the uncoating inhibitor NES-
CPSF6 blocks HIV-1 replication before nuclear import
[33,34,51]. An alternative possibility is that a block tocess of HIV-1.
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cores in the cytosol resulting in an inhibition of the uncoat-
ing process of HIV-1.
Conclusions
Overall, our work showed that MxB binds to the HIV-1
core and prevents the uncoating process of HIV-1. In
addition, we demonstrated that MxB requires capsid bind-
ing and oligomerization for restriction.
Methods
Protocols for each methodology used in this manuscript
are explained in detail in Additional file 5.
Infection with viruses expressing green fluorescent
protein (GFP)
Recombinant HIV-1 expressing GFP was prepared as
described [23]. Recombinant viruses were pseudotyped
with the VSV-G glycoprotein. For infections, 3 × 104
HeLa, U937 or Cf2Th cells seeded in 24-well plates
were incubated at 37°C with virus for 24 h. Cells were
washed and returned to culture for 48 h, and then
GFP-positive cells were analyzed using a flow cytometer
(Becton Dickinson).
Binding of MxB variants to in vitro assembled HIV-1
capsid-nucleocapsid (CA-NC) complexes
The binding of different proteins to in vitro assembled
HIV-1 CA-NC complexes that do or do not contain capsid
changes was carried out as previously described [24,25]. In-
put and bound fractions were analyzed by Western blot-
ting using the indicated antibodies.
Fate of the capsid assay
The fate of the capsid assay was performed as previously
described [25,28,29]. Cells infected for 16 hours were
lysed using 15 strokes in a 7.0 ml Dounce homogenizer
with pestle B. Cellular debris was cleared by centrifuga-
tion for 3 minutes at 3000 rpm. The cleared lysate was
layered onto a 50% sucrose (weight: volume) cushion in
1× PBS and centrifuged at 125,000 × g for 2 hours at 4°C
in a Beckman SW41 rotor. Input, soluble and pellet frac-
tions were analyzed by Western blotting using the indi-
cated antibodies.
Creation of cells stably expressing wild type and mutant
MxB proteins
Cell lines stably expressing wild type or mucbltant MxB
proteins were created using the LPCX vector system
(Clontech), as previously described [25,29,52]. The MxB
proteins contained either an influenza hemagglutinin (HA)
epitope tag or a FLAG epitope tag at the C terminus.MxB oligomerization assay
The ability of MxB to oligomerize was determined by
measuring the interaction of an MxB-FLAG protein with
an MxB-HA protein. Immunoprecipitates were analyzed
by Western blotting using either anti-HA or anti-FLAG
antibodies (Sigma).Additional files
Additional file 1: Restriction of HIV-1 and other viruses by MxB.
(A) HeLa cells stably expressing MxB (bottom panel) were challenged
using increasing amounts of HIV-1-GFP. Forty-eight hours post-infection
the percentage of GFP-positive cells was determined by flow cytometry.
As a control, HeLa cells stably transduced with the empty vector LPCX
were challenged with HIV-1. Similar results were obtained in three
independent experiments and a representative experiment is shown.
(B) U937 cells stably expressing MxB (bottom panel) were challenged
with HIV-1-GFP and SIVmac-GFP. Forty-eight hours post-infection the
percentage of GFP-positive cells was determined by flow cytometry.
As a control, U937 cells stably transduced with the empty vector LPCX
were challenged with HIV-1-GFP. Similar results were obtained in three
independent experiments and a representative experiment is shown.
(C) Cf2Th cells stably expressing MxB (bottom panel) were challenged
with HIV-1-GFP, HIV-2-GFP, SIVmac-GFP, BIV-GFP, FIV-GFP, EAIV-GFP,
N-MLV-GFP and BMLV- GFP. Forty-eight hours post-infection the percentage
of GFP-positive cells was determined by flow cytometry. As a control, Cf2Th
cells stably transduced with the empty vector LPCX were challenged with
the indicated viruses. Similar results were obtained in three independent
experiments and a representative experiment is shown. (D) The ability of
MxB to bind in vitro assembled SIVmac (left panel) or HIV-2 (right panel)
CA-NC complexes was measured, as described in experimental procedures.
Bound fractions were analyzed using anti-HA, anti-p27 and anti-HIV-2-p24
antibodies. Similar results were obtained in three independent experiments
and a representative experiment is shown.
Additional file 2: Restriction of HIV-1 infection by MxB. (A) Cf2Th
cells stably expressing MxB or TRIM5αrh were challenged with increasing
amounts of HIV-1-GFP. Forty-eight hours post-infection the percentage of
GFP-positive cells was determined by flow cytometry. As a control, Cf2Th
cells stably transduced with the empty vector LPCX were challenged with
HIV-1-GFP. (B) Cf2Th cells stably expressing MxB were challenged with
increasing amounts of HIV-1, HIV-1-P90A, HIV-1-G89V or HIV-1-N57S
expressing GFP as a reporter of infection. As a control, Cf2Th cells stably
transduced with the empty vector LPCX were challenged with HIV-1-GFP.
(C) Infectious units (IU) per ng of reverse transcriptase (RT) were measured
for HIV-1, HIV-1-P90A, HIV- 1-G89V, and HIV-1-N57S. (D) The ability of CPSF6-
FLAG to bind in vitro assembled HIV-1 CA-NC complexes bearing capsid
changes P90A, G89V and N57S was measured as described in experimental
procedures. As expected, CPSF6 binds in vitro assembled HIV-1 CA-NC
complexes bearing changes P90A and G89V when compared to wild type
(left panel). In agreement with findings suggesting that N57 is in the capsid
region that interacts with CPSF6, we showed that CPSF6 poorly binds
in vitro assembled HIV-1 CA-NC complexes bearing the change N57S (left
panel). At the same time, the ability of TRIM5αrh to bind in vitro assembled
HIV-1 CA-NC complexes bearing the change N57S was tested (right panel).
(E) In vitro assembled HIV-1 CA-NC complexes bearing the capsid changes
P90A, G89V and N57S were negatively stained and analyzed by transmission
electron microscopy. Representative fields are shown, and the scale bar
corresponds to 100 nm. (F) Cf2Th cells stably expressing MxB, NES-CPSF6
or TRIM5αrh were challenged with increasing amounts of HIV-1-GFP.
Forty-eight hours postinfection the percentage of GFP-positive cells was
determined by flow cytometry. As a control, Cf2Th cells stably transduced
with the empty vector LPCX were challenged with HIV-1-GFP.
Additional file 3: Role of Cyclophilin A in MxB restriction. (A) Cf2Th
cells stably expressing MxB or TRIMCyp were challenged with increasing
amounts of HIV-1-GFP in the presence of 10 μM cyclosporine A (CsA).
Forty-eight hours post-infection the percentage of GFP-positive cells was
determined by flow cytometry. As a control, Cf2Th cells stably transduced
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results were obtained in three independent experiments and a representative
experiment is shown. (B) The ability of MxB and TRIMCyp to bind in vitro
assembled HIV-1 CANC complexes in the presence of 10 μM CsA was
measured, as described in Experimental Procedures. Similar results
were obtained in three independent experiments and a representative
experiment is shown. (C) The ability of MxB to recruit endogenously
expressed cyclophilin A to in vitro assembled HIV-1 CA-NC complexes was
measured by performing a capsid binding assay, as describe in experimental
procedures. Input and Bound fractions were analyzed by Western blotting
using antibodies against FLAG, cyclophilin A and p24. Similar results were
obtained in three independent experiments and a representative
experiment is shown.
Additional file 4: Binding of MxB variants to in vitro assembled
HIV-1 CANC complexes. The ability of wild type and mutant MxB
proteins to bind in vitro assembled HIV-1 CA-NC complexes was measured,
as described in experimental procedures. Input and bound fractions were
analyzed by Western blotting using anti-FLAG and anti-p24 antibodies.
Similar results were obtained in three independent experiments and a
representative experiment is shown.
Additional file 5: Detailed explanation of used methodologies.
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